Our team is primarily focused on clinical research in adolescent girls and women with bleeding disorders and in conducting clinical trials focused on hemophilia A with and without inhibitors. Our institution created the Atlanta Protocol which combines FVIII ITI with Hemlibra and this is under investigation in clinical trials.
Robert F. Sidonio, Jr. MD, MSc
Fun Fact: I love playing tennis and the ukulele.
Megan Brown, MD, MSc (Assistant Professor, Pediatric Hematology/Oncology)
Education: Undergraduate, Michigan State University; MD, Michigan State University College of Human Medicine; MSc, Emory University; Residency (Pediatrics), University of Colorado-Denver; Fellowship, Emory University
Current Projects: Mexico Inhibitor Study and comparative effectiveness of heavy menstrual bleeding treatment.
Current Funding: National Hemophilia Foundation Takeda Clinical Fellowship
Fun Fact: I played college soccer and still love playing sports and being active.
Patel AM, Corman SL, Chaplin S, Raimundo K, Sidonio RF. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22(12):1328‐1337. doi:10.1080/13696998.2019.1669614
Sidonio RF, Zimowski KL. TFPI blockade: removing coagulation's brakes. Blood. 2019;134(22):1885‐1887. doi:10.1182/blood.2019002900
Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio RF Jr. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia. 2019;25(5):789‐796. doi:10.1111/hae.13819
Candy V, Whitworth H, Grabell J, Thibeault L, Harpell L, Bowman M, Good D, Hopman WM, Sidonio RF Jr., James PD. A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding. Blood Adv. 2018;2(20):2629‐2636. doi:10.1182/bloodadvances.2018023713
Anderst JD, Carpenter SL, Presley R, Berkoff MC, Wheeler AP, Sidonio RF Jr., Soucie JM. Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. Pediatrics. 2018;141(5):e20173485. doi:10.1542/peds.2017-3485
Grifols: Mexico Inhibitor Study (investigator-initiated) – 12/2017-12/2020
Goal: To estimate the prevalence of low and high titer inhibitors in a pilot population of moderate and severe hemophilia A patients in Mexico City, Mexico
ATHN 9 VWD (Shire) – 12/2017-12/2021
Goal: To characterize patients with symptomatic VWD and severe VWD in the United States enrolled in the ATHNdataset
Genentech/Octapharma: Emi Pups and Nuwiq ITI study (investigator-initiated) – 05/2018-05/2024
Goal: To assess the safety, immunogenicity, hemostatic efficacy and pharmacokinetics of Emicizumab in PUPs and MTPs with severe hemophilia A (baseline FVIII <1%) and to investigate the feasibility of a modified low dose FVIII ITI while on Emicizumab prophylaxis
Octapharma: MOTIVATE study (investigator-initiated) – 12/2018-12/2023
Goal: A prospective (and partly retrospective), observational, international study to capture different approaches to ITI (Emicizumab only, Bypassing agent only and the Atlanta Protocol)